Abstract: The disclosure provides peptides, including labeled peptides, that selectively bind to the cMet protein. The disclosure also provides methods of detecting dysplastic cells and tissue, e.g., in the colon, providing early identification of precancerous and cancerous tissue.

Abstract: The disclosure discloses a fusion albumin nanoparticle and application thereof, and belongs to the technical field of biomedicine. In the disclosure, fusion albumin is expressed by using a genetic engineering technology, and the fusion albumin nanoparticle is formed by performing self-assembly and drug loading on the fusion albumin in a neutral aqueous solution. The fusion albumin studied in the disclosure has targetability, pH and enzyme-sensitive functional groups, the nanoparticle prepared by using the fusion albumin has the functions of targetability and controlled drug release, and a method for preparing the fusion albumin nanoparticle is simple and easy to implement and has great application potential.

Abstract: The present invention is directed to glypican-3-specific peptide reagents, methods for detecting hepatocellular carcinoma cells using the peptide reagents, and methods for targeting hepatocellular carcinoma cells using the peptide reagents.

Abstract: The present invention relates to an additive composition for abatement of free aldehydes, particularly formaldehyde, or removing the same in the air, comprising—a polymer of acetoacetyl functional ethylenically unsaturated monomer, which contains at least 70 wt % of at least one acetoacetyl functional ethylenically unsaturated monomer, and 0 to 30 wt % of at least one ethylenically unsaturated monomer other than the acetoacetyl functional ethylenically unsaturated monomer, based on the total weight of all monomer(s), and—optionally, at least one amine, and to an interior coating composition comprising the additive composition.

Abstract: A five-membered heterocyclic amide WNT pathway inhibitor having the following general structural formula: The five-membered heterocyclic amide WNT pathway inhibitor has a remarkable anti-tumor activity based on a target-based rational drug design, and can be used for the development of a new generation of Wnt pathway inhibitors, and has a great clinical application value and considerable market potential.

Abstract: The present invention discloses a compound for regulating protein kinase activity and used for treating or preventing diseases associated with protein kinases. Specifically, the present invention relates to a benzofuran pyrazole amine protein kinase inhibitor which belongs to compounds that regulate anaplastic lymphoma kinase (ALK), and provides a method of preparing such a compound and a pharmaceutical use of such a compound in the treatment or prevention of diseases associated with ALK. The inhibitor can solve the problem of the drug resistance of the first generation and the second generation of ALK inhibitors.

Abstract: The present disclosure relates to Fibroblast Growth Factor Receptor 2-specific peptide reagents, methods for detecting epithelial-derived cancer cells such as esophageal, colorectal, gastric, pancreatic or breast carcinoma cells using the peptide reagents, and methods for targeting such cells using the peptide reagents.

Abstract: The present invention is directed to EGFR-specific and ErbB2-specific peptide reagents, methods for detecting pre-cancer, early cancer and/or cancer using the peptide reagents alone or in a multiplex format, and methods for targeting pre-cancer cells, early cancer cells and/or cancer cells using the peptide reagents.

Abstract: The present invention is directed to glypican-3-specific peptide reagents, methods for detecting hepatocellular carcinoma cells using the peptide reagents, and methods for targeting hepatocellular carcinoma cells using the peptide reagents.

Abstract: The present invention is directed to EGFR-specific peptide reagents, methods for detecting pre-cancer, early cancer and/or cancer using the peptide reagents, and methods for targeting pre-cancer cells, early cancer cells and/or cancer cells using the peptide reagents. In one aspect, the disclosure provides reagents consisting essentially of a peptide QRHKPRE (SEQ ID NO: 1), HAHRSWS (SEQ ID NO: 2), YLTMPTP (SEQ ID NO: 3), TYPISFM (SEQ ID NO: 4), KLPGWSG (SEQ ID NO: 5), IQSPHFF (SEQ ID NO: 6), YSIPKSS (SEQ ID NO: 7), SHRNRPRNTQPS (SEQ ID NO: 8), NRHKPREKTFTD (SEQ ID NO: 9).

Abstract: Provided are ligands comprising a non-naturally occurring peptide that binds a cysteine rich domain (CRD) of the Frizzled7 (FZD7) receptor. Additionally, provided are therapeutic methods of using such ligands, as well as compositions comprising such ligands.

Abstract: The gamma compensation circuit includes a gamma circuit, a source driver, a TFT, a liquid crystal capacitor, a common voltage circuit, and an adjustment circuit. The gamma circuit has an output terminal connected to an input terminal of the source driver. The source driver has an output an output terminal connected to the source of the TFT. The TFT's drain is connected to a first terminal of the liquid crystal capacitor. The liquid crystal capacitor has a second terminal connected to an output terminal of the common voltage circuit. The adjustment circuit has a first terminal connected to a junction of the output terminal of the gamma circuit and the input terminal of the source driver. The adjustment circuit has a second terminal connected to another junction of the second terminal of the liquid crystal capacitor and the output terminal of the common voltage circuit.

Abstract: The present invention discloses a compound for regulating protein kinase activity and used for treating or preventing diseases associated with protein kinases. Specifically, the present invention relates to a benzofuran pyrazole amine protein kinase inhibitor which belongs to compounds that regulate anaplastic lymphoma kinase (ALK), and provides a method of preparing such a compound and a pharmaceutical use of such a compound in the treatment or prevention of diseases associated with ALK. The inhibitor can solve the problem of the drug resistance of the first generation and the second generation of ALK inhibitors.

Abstract: Provided are a high-quality, lithium-rich and manganese-based positive electrode material for a lithium ion battery and a method for synthesizing same. The method comprises the following steps: preparing a precursor by complexing an amino acid and a nickel-cobalt-manganese metal, mixing the above-mentioned precursor with a lithium salt, and subjecting same to ball-milling, drying and calcination to obtain a finished product. The amino acid is used as a complexing agent, benefiting the coprecipitation of the three transition metals, achieving the uniform distribution of each metal element in a material, improving the comprehensive electrochemical performance of a lithium-rich and manganese-based material, and improving the quality of the material. The lithium-rich and manganese-based material prepared by the method has characteristics such as a high tapped density, a high compaction density, and a better electrochemical performance.

Abstract: A self-interference channel estimation method and device, where the method includes: determining, when a receive port of the first device receives a first signal, a second signal transmitted by a transmit port of the first device, wherein the first signal comprises a service signal from a second device, and comprises a self-interference signal originated from the second signal interfering, through an air interface, with the service signal from the second device, wherein service data comprised in the second signal is segmented into at least two segments, and a signal sequence formed by at least one preset character is inserted between the at least two segments of service data; estimating, according to the first signal and the second signal, the self-interference signal originated from the second signal; and eliminating the estimated self-interference signal from the received first signal.

Abstract: The present invention discloses a five-membered heterocyclic amide WNT pathway inhibitor, which belongs to a compound that regulates the activity of a Wnt signaling pathway, and provides a method for preparing such a compound, and the use of such a compound in preparing a medicament that antagonizes the Wnt signaling pathway. The five-membered heterocyclic amide WNT pathway inhibitor provided by the invention has a remarkable anti-tumor activity based on a target-based rational drug design of, and can be used for the development of a new generation of Wnt pathway inhibitors, and has a great clinical application value and considerable market potential.

Abstract: A modulation policy for a modular multi-level convertor, determining a switching state of each submodule by combining the current direction of each bridge arm and the capacitor voltage order of the submodules based on a carrier stacking method. The beneficial effects of the modulation policy are that: each phase only needs a modulation wave and N carriers, given N submodules of each upper bridge arm or lower bridge arm of the modular multi-level convertor; the modular multi-level convertor can output N+1 levels without carrier phase shift; N devoted submodules of each phase are guaranteed at any time; and the submodules' capacitor voltage balancing can be controlled without a closed-loop control policy. The modulation policy facilitates adjustment of the modular multi-level convertor voltage and power class, has unlimited number of levels, has a high precision control algorithm, is easy to realize in engineering and saves software and hardware resources.

Abstract: The present invention is directed to EGFR-specific peptide reagents, methods for detecting pre-cancer, early cancer and/or cancer using the peptide reagents, and methods for targeting pre-cancer cells, early cancer cells and/or cancer cells using the peptide reagents. In one aspect, the disclosure provides reagents consisting essentially of a peptide QRHKPRE (SEQ ID NO: 1), HAHRSWS (SEQ ID NO: 2), YLTMPTP (SEQ ID NO: 3), TYPISFM (SEQ ID NO: 4), KLPGWSG (SEQ ID NO: 5), IQSPHFF (SEQ ID NO: 6), YSIPKSS (SEQ ID NO: 7), SHRNRPRNTQPS (SEQ ID NO: 8), NRHKPREKTFTD (SEQ ID NO: 9).

Abstract: A self-interference channel estimation method and device, where the method includes: determining, when a receive port of the first device receives a first signal, a second signal transmitted by a transmit port of the first device, wherein the first signal comprises a service signal from a second device, and comprises a self-interference signal originated from the second signal interfering, through an air interface, with the service signal from the second device, wherein service data comprised in the second signal is segmented into at least two segments, and a signal sequence formed by at least one preset character is inserted between the at least two segments of service data; estimating, according to the first signal and the second signal, the self-interference signal originated from the second signal; and eliminating the estimated self-interference signal from the received first signal.

Abstract: A modulation policy for a modular multi-level convertor, determining a switching state of each submodule by combining the current direction of each bridge arm and the capacitor voltage order of the submodules based on a carrier stacking method.